Gemcitabine in bladder cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3251-3256

  El Karak, Fadi ^a   Flechon, Aude ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

antimetabolite; bladder cancer; gemcitabine; urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; TAXOID;

BLADDER TUMOR; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY; REVIEW; UROTHELIUM;

ADMINISTRATION, INTRAVESICAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; HUMANS; TAXOIDS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 40949141574     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3251     Document Type: Article

References (49)

1. GUCHELAAR HJ, RICHEL DJ, VAN KNAPEN A: Clinical toxicological and pharmacological aspects of Gemcitabine. Cancer Treat. Rev. (1996) 22:15-31.
2. AAPRO MS, MARIN C, HATTY S: Review paper: gemcitabine-a safety review. Anti Cancer Drugs (1998) 9:191-201.
3. STADLER WM, KUZELT, ROTH B, RAGHAVAN D, DORR FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. (1997) 15 (11):3394-3398.
4. MOORE MJ, TANNOCK IF, ERNST DS, HUAN S, MURRAY N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol (1997) 15(12):3441-3445.
5. ABRATT RP, BEZWODA WR, FALKSON G, GOEDHALS L, HACKING D, RUGG TA: Effi cacy and safety profi le of gemcitabine in non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. (1994) 12(8):1535-1540.
6. DALBAGNI G, RUSSO P, BOCHNER B et al. : Phase II trial of intravesical gemcitabine in B acille Calmette-Gu érin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. (2006) 20:2729-2734.
7. MAFFEZZINI M, CAMPODONICO F, CANEPA G, CAPPONI G, FONTANA V: Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low-or intermediate-risk, transitional cell carcinoma of the bladder. Eur. Urol. (2007) 51(4):956-961.
8. FLECHON A, FIZAZI K, GOURGOU-BOURGADE S et al.: Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-urinary group of the French federation of cancer centers. Anti Cancer Drugs (2006) 17(6):705-708.
9. VON DER MAASE H, HANSEN SW, ROBERTS JT et al. : Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. (2000) 18(17):3068-3077.
10. POLLERA CF, CERIBELLI A, CRECCO M, CALABRESI F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a Phase I study. Ann. Oncol. (1994) 5(2):182-184.
11. LORUSSO V, POLLERA CF, ANTIMI M et al. : A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian co-operative group on bladder cancer. Eur. J. Cancer (1998) 34(8):1208-1212.
12. GEBBIA V, TESTA A, BORSELLINO N et al. : Single agent 2 ′,2′-difl uorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a Phase II study. Clin. Ther. (1999) 150(1):11-15.
13. SHIPLEY WU, KAUFMAN DS, MCDOUGAL WS et al. : Cancers of the genitourinary system (Section 2): cancers of the bladder, ureter, and renal pelvis). In: Cancer: Principles and Practice of Oncology (7th Edition). DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincot and Williams, Philadelphia (PA) ( 2004 ).
14. PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMANG, KUIPER CM, BRAAKHUIS BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. (1995) 22 (4 Suppl. 11):72-79.
15. VON DER MAASE H, ANDERSEN L, CRINO L, WEINKNECHT S, DOGLIOTTI L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann. Oncol. (1999) 10(12):1461-1465.
16. MOORE MJ, WINQUIST EW, MURRAY N et al. : Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National cancer institute of Canada clinical trials group. J. Clin. Oncol. (1999) 17(9):2876-2881.
17. KAUFMAN D, RAGHAVAN D, CARDUCCI M et al. : Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. (2000) 18(9):1921-1927.
18. VON DER MAASE H: Gemcitabine and cisplatin in locally advanced and/or metastatic blaccer cancer. Eur. J. Cancer (2000) 36(Suppl. 2):13-16.
19. LORUSSO V, MANZIONE L, DE VITA F, ANTIMI M, SELVAGGI F P, DE LENA M: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a Phase II multicenter trial. J. Urol. (2000) 164(1):53-56.
20. VON DER MAASE H, SENGELOV L, ROBERTS JT et al. : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. (2005) 23(21):4602-4608.
21. BAMIAS A, MOULOPOULOS LA, KOUTRAS A et al. : The combination of gemcitabine and carboplatin as fi rst-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic cooperative oncology group. Cancer (2006) 106(2):297-303.
22. NOGUE-ALIGUER M, CARLES J, ARRIVI A et al. : Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer (2003) 97(9):2180-2186.
23. SHANNON C,CROMBIE C,BROOKS A,LAU H,DRUMMOND M,GURNEY H:Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features, Ann. Oncol., 2001,12, 7. 947-952
24. STERNBERG CN, CALABRO F, PIZZOCARO G, MARINI L, SCHNETZER S, SELLA A: Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer (2001) 92(12):2993-2998.
25. FECHNER GH, SIENER R, REIMANN M et al.: Randomized Phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J. Urol. (2002) 167(4 Suppl.):284 (Abstr.).
26. MELUCH AA, GRECO FA, BURRIS HA et al. : Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of the Minnie pearl cancer research network. J. Clin. Oncol. (2001) 19(12):3018-3024.
27. LI J, JULIAR B, YIANNOUTSOS C, ANSARIR et al. : Weekly paclitaxel and gemcitabine in advanced transitional cell carcinoma of the urothelium: a Phase II Hoosier oncology group study. J. Clin. Oncol. (2005) 23(6):1185-1191.
28. KAUFMAN DS, CARDUCCI MA, KUZEL TM et al. : A multi-institutional Phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol. Oncol. (2004) 22(5):393-397.
29. CALABRO F, STERNBERG CN, LORUSSO V et al. : Multicenter Phase II study of every-2 week gemcitabine and paclitaxel as fi rst-line chemotherapy in patients with advanced urothelial tract cancer. J. Clin. Oncol. (2005) 23 (S16), Part I of II (June 1 Suppl.) (Abstr. 4583).
30. GITLITZ BJ, BAKER C, CHAPMAN Y et al. : A Phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer (2003) 98(9):1863-1869.
31. DREICER R, MANOLA J, SCHNEIDER DJ et al. : Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern cooperative oncology group. Cancer (2003) 97(11):2743-2747.
32. ARDAVANIS A,TRYFONOPOULOS D, ALEXOPOULOS A, KANDYLIS C, LAINAKIS G, RIGATOS G: Gemcitabine and docetaxel as fi rst-line treatment for advanced urothelial carcinoma: a Phase II study. Br. J. Cancer (2005) 92(4):645-650.
33. PECTASIDES D, ARAVANTINOS G, KALOFONOS H et al.: Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A Phase II trial conducted by the Hellenic cooperative oncology group. Ann. Oncol. (2001) 12(10):1417-1422.
34. BELLMUNT J, GUILLEM V, PAZ-ARES L et al. : Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish oncology genitourinary group. J. Clin. Oncol. (2000) 18(18):3247-3255.
35. HUSSAIN M,VAISHAMPAYAN U, DU W, REDMAN B, SMITH DC: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. (2001) 19(9):2527-2533.
36. PECTASIDES D, GLOTSOS J, BOUNTOUROGLOU N et al.: Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a Phase II trial. Ann. Oncol. (2002) 13(2):243-250.
37. BELLMUNT J, VON DER MAASE H, MEAD JM et al.: Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup study. J. Clin. Oncol., ASCO Annual Meeting Proceedings. Part I. (2007) 25(S18) (June 20 Suppl.):LBA5030.
38. SMALL EJ, HALABI S, DALBAGHNI G et al. : Overview of bladder cancer trials in the cancer and leukemia group B. Cancer (2003) 97(8 Suppl.):2090-2098.
39. ARTZ A, STADLER WM, VOGELZANG NJ, ZIMMERMAN T, RYAN C: A Phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am. J. Clin. Oncol. (2005) 28(2):109-113.
40. LLADO A, BELLMUNT G, KAISER G, DE WIT R, GOBARTT E, BASELGA J: A dose fi nding study of carboplatin with fi xed doses of gemcitabine in "unfi t" patients with advanced bladder cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:A344.
41. LINARDOU H, ARAVANTINOS G, EFSTATHIOU E et al. : Gemcitabine and carboplatin combination as fi rst-line treatment in elderly patients and those unfi t for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic co-operative oncology group. Urology (2004) 64(3):479-484.
42. CARLES J, NOGUE M, DOMENECH M et al. : Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology (2000) 59(1):24-27.
43. BELLMUNT J, DE WIT R, ALBANELL J, BASELGA J: A feasibility study of carboplatin with fi xed dose of gemcitabine in "unfi t" patients with advanced bladder cancer. Eur. J. Cancer (2001) 37(17):2212-2215.
44. CARLES J, ESTEBAN E, CLIMENT MA et al. : Gemcitabine and oxaliplatin combination: a multicenter Phase II trial in unfi t patients with locally advanced or metastatic urothelial cancer. Ann. Oncol. (2007) 18:1359-1362.
45. HUSSAIN SA, STOCKEN DD, RILEY P et al. : A Phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. BJC (2004) 91:844-849.
46. MCHUGH LA, KRIAJEVSKA M, MELLON JK, GRIFFITHS TR: Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens. Evidence of schedule-dependent synergy. Urology (2007) 69:390-394.
47. KRAUSE S, FORSTER Y, KRAEMER K, FUESSEL S, KOTZCH M, SCMIDT U et al. : Vascular endothelial growth factor antisense pre-treatment of bladder cancer cells signifi cantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin. J. Urol. (2005) 174 :328-331.
48. KAMAT AM, KARASHIMAT, DAVIS DW, LASHINGER L, BAR-ELI M, MILIKAN R et al.: the proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253 JB-V bladder tumors in vivo. Mol. Cancer Ther. (2004) 3 :279-290.
49. HUSSAIN MMH, MACVICAR GR, PETRYLAK DP, DUNN RL, VAISHAMPAYAN U, LARA PN et al.: Trastuzumab, paclitaxel, carboplatin and gemcitabin in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of phase II National Cancer Institute trial. J. Clin. Oncol. (2007) 25 :2218-2224.